After a record run, fewer biotechs are going public. Here’s how they’re performing.

After a record run, fewer biotechs are going public. Here’s how they’re performing.

Source: 
BioPharma Dive
News Tags: 
snippet: 

Initial public offerings are a critical source of funding for young drugmakers. Keep track of them as they happen with this database.